You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC / CE

Should Cardiovascular Risk Assessment Be Different for Women Than for Men?

  • Authors: News Author: Megan Brooks; CME Author: Charles P. Vega, MD  
  • CME / ABIM MOC / CE Released: 5/12/2023
  • Valid for credit through: 5/12/2024, 11:59 PM EST
Start Activity

  • Credits Available

    Physicians - maximum of 0.25 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.25 ABIM MOC points

    Nurses - 0.25 ANCC Contact Hour(s) (0 contact hours are in the area of pharmacology)

    Pharmacists - 0.25 Knowledge-based ACPE (0.025 CEUs)

    Physician Assistant - 0.25 AAPA hour(s) of Category I credit

    IPCE - 0.25 Interprofessional Continuing Education (IPCE) credit

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for primary care clinicians, cardiologists, nurses, pharmacists, physician assistants, and other clinicians who treat and manage women.

The goal of this activity is for learners to be better able to assess cardiovascular risk factors and interventions for women.

Upon completion of this activity, participants will

  • Assess disparities for cardiovascular risk factors among women of color
  • Distinguish interventions to improve the cardiovascular health of women
  • Outline implications for the healthcare team


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


News Author

  • Megan Brooks

    Freelance writer, Medscape

    Disclosures

    Megan Brooks has no relevant financial relationships.

CME Author

  • Charles P. Vega, MD

    Health Sciences Clinical Professor of Family Medicine
    University of California, Irvine School of Medicine

    Disclosures

    Charles P. Vega, MD, has the following relevant financial relationships:
    Consultant or advisor for: Boehringer Ingelheim; GlaxoSmithKline; Johnson & Johnson

Editor/Nurse Planner

  • Leigh Schmidt, MSN, RN, CNE, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Compliance Reviewer

  • Amanda Jett, PharmD, BCACP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Amanda Jett, PharmD, BCACP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements

Medscape

Interprofessional Continuing Education

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

IPCE

This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 credit™ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

    College of Family Physicians of Canada Mainpro+® participants may claim certified credits for any AMA PRA Category 1 credit(s)™, up to a maximum of 50 credits per five-year cycle. Any additional credits are eligible as non-certified credits. College of Family Physicians of Canada (CFPC) members must log into Mainpro+® to claim this activity.

    Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

    Contact This Provider

    For Nurses

  • Awarded 0.25 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.00 contact hours are in the area of pharmacology.

    Contact This Provider

    For Pharmacists

  • Medscape designates this continuing education activity for 0.25 contact hour(s) (0.025 CEUs) (Universal Activity Number: JA0007105-0000-23-171-H01-P).

    Contact This Provider

  • For Physician Assistants

    Medscape, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until 5/12/2024. PAs should only claim credit commensurate with the extent of their participation.

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC / CE

Should Cardiovascular Risk Assessment Be Different for Women Than for Men?

Authors: News Author: Megan Brooks; CME Author: Charles P. Vega, MD  Faculty and Disclosures

CME / ABIM MOC / CE Released: 5/12/2023

Valid for credit through: 5/12/2024, 11:59 PM EST

processing....

Clinical Context

Research and prevention strategies for cardiovascular disease have historically been focused on White men, but the American Heart Association (AHA) has shifted its emphasis to be more inclusive of women and racial/ethnic minorities. The current AHA Scientific Statement recommends the evaluation for a host of cardiovascular risk factors particular to women. These include pregnancy-related disease states such as preeclampsia and gestational diabetes, as well as menstrual cycle history. Early age at menarche is associated with a higher risk for metabolic syndrome and possibly cardiovascular disease, and early menopause is also associated with negative metabolic outcomes.

Polycystic ovarian syndrome affects 5% to 10% of women of reproductive age and is associated with hypertension as well as disorders of lipid and glucose metabolism. Finally, women suffer much higher rates of autoimmune disorders compared with men, and these disorders are associated with higher rates of systemic inflammation that increase the risk for cardiovascular disease.

There are also important differences between women and men in more traditional cardiovascular risk factors, and these differences are most profound in considering women of color. The current scientific statement provides a review of these important distinctions.

Study Synopsis and Perspective

In a new scientific statement, the AHA highlights the importance of incorporating nonbiological risk factors and social determinants of health in cardiovascular disease (CVD) risk assessment for women, particularly women from different racial and ethnic backgrounds.

CVD risk assessment in women is multifaceted and goes well beyond traditional risk factors to include sex-specific biological risk factors, as well as social, behavioral, and environmental factors, the writing group notes.

They say that a greater focus on addressing all CVD risk factors among women from underrepresented races and ethnicities is warranted to avert future CVD.

The scientific statement was published online April 10 in Circulation.

Look Beyond Traditional Risk Factors

“Risk assessment is the first step in preventing heart disease, yet there are many limitations to traditional risk factors and their ability to comprehensively estimate a woman’s risk for cardiovascular disease,” Jennifer H. Mieres, MD, vice chair of the writing group and professor of cardiology at the Zucker School of Medicine at Hofstra Northwell in Hempstead, New York, says in a news release. 

“The delivery of equitable cardiovascular health care for women depends on improving the knowledge and awareness of all members of the healthcare team about the full spectrum of cardiovascular risk factors for women, including female-specific and female-predominant risk factors,” Dr Mieres adds.

Female-specific factors that should be included in CVD risk assessment include pregnancy-related conditions such as preeclampsia, preterm delivery, and gestational diabetes, the writing group says.

Other factors include menstrual cycle history; types of birth control and/or hormone replacement therapy used; polycystic ovarian syndrome, which affects 10% of women of reproductive age and is associated with increased CVD risk; and autoimmune disorders, depression, and posttraumatic stress disorder, all of which are more common in women and are also associated with higher risk for CVD.

The statement also highlights the key role that social determinants of health (SDOH) play in the development of CVD in women, particularly women from diverse racial and ethnic backgrounds. SDOH include education level, economic stability, neighborhood safety, working conditions, environmental hazards, and access to quality health care.

“It is critical that risk assessment be expanded to include [SDOH] as risk factors if we are to improve health outcomes in all women,” Laxmi S. Mehta, MD, chair of the writing group and director of preventative cardiology and women’s cardiovascular health at The Ohio State University Wexner Medical Center in Columbus, says in the news release.

“It is also important for the healthcare team to consider [SDOH] when working with women on shared decisions about cardiovascular disease prevention and treatment,” Dr Mehta notes.

No One-Size-Fits-All Approach

The statement highlights significant differences in CVD risk among women of different racial and ethnic backgrounds and provides detailed CV risk factor profiles for non-Hispanic Black, Hispanic/Latinx, Asian, and American Indian/Alaska Native women.

It notes that language barriers, discrimination, acculturation, and healthcare access disproportionately affect women of underrepresented racial and ethnic groups. These factors result in a higher prevalence of CVD and significant challenges in CVD diagnosis and treatment.

“When customizing CVD prevention and treatment strategies to improve cardiovascular health for women, a one-size-fits-all approach is unlikely to be successful,” Dr Mieres says.

“We must be cognizant of the complex interplay of sex, race and ethnicity, as well as social determinants of health, and how they impact the risk of cardiovascular disease and adverse outcomes in order to avert future CVD morbidity and mortality,” Dr Mieres adds.

Looking ahead, the writing group says that future CVD prevention guidelines could be strengthened by including culturally specific lifestyle recommendations.

They also say that community-based approaches, faith-based community partnerships, and peer support to encourage a healthy lifestyle could play a key role in preventing CVD among all women.

This scientific statement was prepared by the volunteer writing group on behalf of the American Heart Association’s Cardiovascular Disease and Stroke in Women and Underrepresented Populations Committee of the Council on Clinical Cardiology, the Council on Cardiovascular and Stroke Nursing, the Council on Hypertension, the Council on Lifelong Congenital Heart Disease and Heart Health in the Young, the Council on Lifestyle and Cardiometabolic Health, the Council on Peripheral Vascular Disease, and the Stroke Council.

Circulation. Published online April 10, 2023.[1]

Study Highlights

  • The prevalence of all cardiovascular disease, including hypertension, among US Black women at least 20 years of age approaches 60%. Nearly 43% of Hispanic women have some form of cardiovascular disease.
  • Although higher rates of cardiovascular disease promote a 5-year lower difference in life expectancy in comparing Black and White women, Hispanic women have lower rates of cardiovascular death compared with White women.
  • The prevalence of cardiovascular disease is variable among American Indian/Alaska Native women based on region, with the highest rates found in the Northern and Southern Plains.
  • Asian women have lower rates of cardiovascular death compared with White women. In the Asian diaspora, the highest rates of cardiovascular death are among women with Indian or Filipina ancestry.
  • Black women in the US have the highest prevalence of hypertension in the world (55.3%). Black women are less likely to have controlled hypertension compared with White women, but Mexican American women have even lower rates of hypertension control.
  • It is estimated that 25% to 41% of American Indian/Alaska Native women have hypertension. One study found that death resulting from hypertensive disease was more common among Asian vs White women.
  • Black women have higher rates of dyslipidemia compared with White women, and they have the highest levels of lipoprotein(a) compared with other racial/ethnic groups.
  • 37.3% of Hispanic women have a total cholesterol level in excess of 200 mg/dL, and approximately 20% of American Indian/Alaska Native women have been diagnosed with dyslipidemia.
  • The prevalence rates of diabetes among American Indian/Alaska Native, Hispanic, Black, and White women are 19%, 14.1%, 13.2%, and 7.3%, respectively. The prevalence rates of obesity among American Indian/Alaska Native, Hispanic, Black, and White women are 48.1%, 48.4%, 55.3%, and 37.8%, respectively.
  • Asian adults have higher rates of hypertension, type 2 diabetes, and cardiovascular disease compared with White adults with the same body mass index. Therefore, the World Health Organization and American Diabetes Association have suggested dropping the definition of overweight and obesity among persons of Asian descent to 23 and 27.5 kg/m2, respectively.
  • Social determinants of health disproportionately affect women of color and contribute to higher rates of cardiovascular disease. Asian women in the US are exposed to higher levels of air pollution, and exposures to lead and arsenic are higher in Black and Hispanic women, respectively. Living in socially disenfranchised communities raises the risks for obesity and hypertension.
  • The AHA has some specific recommendations to help reduce the risk for cardiovascular disease among women of color:
    • Thiazide diuretics should be considered first line for women to help prevent osteoporosis.
    • Women with a history of preeclampsia should have a thorough evaluation for cardiovascular risk factors within 12 months of delivery.
    • Statins should be discontinued 1 to 2 months before pregnancy, when possible, among women at moderate risk for cardiovascular disease, but the continuation of water-soluble statins should be considered among high-risk women during pregnancy.

Implications for the healthcare team

  • Black women in the US have the highest prevalence of hypertension in the world (55.3%). Higher rates of cardiovascular disease promote a 5-year lower difference in life expectancy in comparing Black and White women. Black women have the highest levels of lipoprotein(a) compared with other racial/ethnic groups. American Indian and Hispanic women experience higher rates of diabetes compared with Black women.
  • The current statement recommends that thiazide diuretics should be considered first line for women to help prevent osteoporosis. Women suffer much higher rates of autoimmune disorders compared with men, and these disorders should be accounted for in assessing the risk for cardiovascular disease. Women with a history of preeclampsia should have a thorough evaluation for cardiovascular risk factors within 12 months of delivery. Statins should be discontinued 1 to 2 months before pregnancy, when possible, among women at moderate risk for cardiovascular disease, but the continuation of water-soluble statins should be considered among high-risk women during pregnancy.
  • The healthcare team should incorporate nonbiological risk factors and social determinants of health in CVD risk assessment for women, particularly women from different racial and ethnic backgrounds.

 

Earn Credit

  • Print